Andrea Romano

Dr. Andrea Romano

Department of Obstetrics & Gynaecology, GROW-School for Oncology & Developmental Biology, Maastricht University & Medical Centre, P Debyelaan 25, 6202 AZ Maastricht, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ricky KampsRicky Kamps
Ricky Kamps
RBRita Brandão
Rita Brandão
BBBianca J. van Den Bosch
Bianca J. van Den Bosch
APAimée DC Paulussen
Aimée DC Paulussen
SXSofia Xanthoulea
Sofia Xanthoulea
Andrea RomanoAndrea Romano
Andrea Romano
Next-generation sequencing (NGS) technology has expanded in the last decades with significant improvements in the reliability, sequencing chemistry, pipeline analyses, data interpretation and costs. Such advances make the use of NGS feasible in clinical practice today. This review describes the recent technological developments in NGS applied to the field of oncology. A number of clinical applications are reviewed, i.e., mutation detection in inherited cancer syndromes based on DNA-sequencing, detection of spliceogenic variants based on RNA-sequencing, DNA-sequencing to identify risk modifiers and application for pre-implantation genetic diagnosis, cancer somatic mutation analysis, pharmacogenetics and liquid biopsy. Conclusive remarks, clinical limitations, implications and ethical considerations that relate to the different applications are provided.

7 January 2019 in Marine Drugs
Verified
Journal Article
Open access
PDF file
GWGeert Van Weelden
Geert Van Weelden
MBMarcin Bobiński
Marcin Bobiński
KOKarolina Okła
Karolina Okła
WWWillem Jan Van Weelden
Willem Jan Van Weelden
Andrea RomanoAndrea Romano
Andrea Romano
JPJohanna Pijnenborg
Johanna Pijnenborg
Fucoidan is a natural derived compound found in different species of brown algae and in some animals, that has gained attention for its anticancer properties. However, the exact mechanism of action is currently unknown. Therefore, this review will address fucoidans structure, the bioavailability, and all known different pathways affected by fucoidan, in order to formulate fucoidans structure and activity in relation to its anti-cancer mechanisms. The general bioactivity of fucoidan is difficult to establish due to factors like species-related structural diversity, growth conditions, and the extraction method. The main pathways influenced by fucoidan are the PI3K/AKT, the MAPK pathway, and the caspase pathway. PTEN seems to be important in the fucoidan-mediated effect on the AKT pathway. Furthermore, the interaction with VEGF, BMP, TGF-β, and estrogen receptors are discussed. Also, fucoidan as an adjunct seems to have beneficial effects, for both the enhanced effectiveness of chemotherapy and reduced toxicity in healthy cells. In conclusion, the multipotent character of fucoidan is promising in future anti-cancer treatment. However, there is a need for more specified studies of the structure–activity relationship of fucoidan from the most promising seaweed species.

1 July 2007 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
PGP.G. Groothuis
P.G. Groothuis
HDH.H.N.M. Dassen
H.H.N.M. Dassen
Andrea RomanoAndrea Romano
Andrea Romano
Chamindie K. PunyadeeraChamindie K. Punyadeera
Chamindie K. Punyadeera
To date, research into the biological processes and molecular mechanisms associated with endometrial receptivity and embryo implantation has been a focus of attention, whereas the complex events that occur in the human endometrium during the menstrual and proliferative phase under the influence of estrogen have received little attention. The objective of this review is to provide an update of our current understanding of the actions of estrogen on both human and rodent endometrium, with special emphasis on the regulation of uterine growth and cell proliferation, and the value of global gene expression analysis, in increasing understanding of these processes.

28 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NJNadine Jetten
Nadine Jetten
NRNadia Roumans
Nadia Roumans
MGMarion J. Gijbels
Marion J. Gijbels
Andrea RomanoAndrea Romano
Andrea Romano
MPMark J. Post
Mark J. Post
SXSofia Xanthoulea
Sofia Xanthoulea
Macrophages play a crucial role in all stages of cutaneous wound healing responses and dysregulation of macrophage function can result in derailed wound repair. The phenotype of macrophages is influenced by the wound microenvironment and evolves during healing from a more pro-inflammatory (M1) profile in early stages, to a less inflammatory pro-healing (M2) phenotype in later stages of repair. The aim of the current study was to investigate the potential of exogenous administration of M2 macrophages to promote wound healing in an experimental mouse model of cutaneous injury. Bone marrow derived macrophages were stimulated in-vitro with IL-4 or IL-10 to obtain two different subsets of M2-polarized cells, M2a or M2c respectively. Polarized macrophages were injected into full-thickness excisional skin wounds of either C57BL/6 or diabetic db/db mice. Control groups were injected with non-polarized (M0) macrophages or saline. Our data indicate that despite M2 macrophages exhibit an anti-inflammatory phenotype in-vitro, they do not improve wound closure in wild type mice while they delay healing in diabetic mice. Examination of wounds on day 15 post-injury indicated delayed re-epithelialization and persistence of neutrophils in M2 macrophage treated diabetic wounds. Therefore, topical application of ex-vivo generated M2 macrophages is not beneficial and contraindicated for cell therapy of skin wounds.

1 March 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
BDBert Delvoux
Bert Delvoux
PGPatrick Groothuis
Patrick Groothuis
TDThomas D'Hooghe
Thomas D'Hooghe
MKMutinda Mutinda Kyama
Mutinda Mutinda Kyama
GDGerard Dunselman
Gerard Dunselman
Andrea RomanoAndrea Romano
Andrea Romano
Context: substantial evidence suggests that the expression of steroid metabolizing enzymes in endometriosis is altered, turning the ectopic endometrium into a source of 17β-estradiol. However, whether these differences result in a net increase in local 17β-estradiol production/activity has not been shown. Subjects and Methods: The activities of the most important steroidogenic enzymes synthesizing and inactivating 17β-estradiol were determined by HPLC in matched eutopic and ectopic tissue from patients with endometriosis (n = 14) and in endometrium from controls (n = 20). Results: Aromatase activity is negligible in the ectopic endometrium, whereas the activity of estrogen sulfatase is high though not different between ectopic, eutopic and control endometrium. The activity of 17β-hydroxysteroid dehydrogenases (17β-HSDs) converting estrone into 17β-estradiol is higher in the ectopic compared to the eutopic endometrium in patients. The activity of 17β-HSDs converting 17β-estradiol back to estrone is significantly lower in the ectopic compared to the eutopic endometrium of both patients and controls. To evaluate the net metabolic capacity of tissues to synthesize 17β-estradiol, we calculated the activity ratio between 17β-HSDs synthesizing versus 17β-HSDs inactivating 17β-estradiol. This ratio is significantly higher in the ectopic compared to the eutopic endometrium of patients and controls, indicating a high synthesis of 17β-estradiol in the ectopic locations. This is further supported by the elevated mRNA levels of the estrogen-responsive gene TFF1 in all ectopic compared to eutopic endometria. Conclusion: Endometriotic lesions have higher production of 17β-estradiol than the eutopic endometrium of patients and controls. This is mostly the result of impaired metabolism.

27 September 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
LALorena Alonso-Alconada
Lorena Alonso-Alconada
LMLaura Muinelo
Laura Muinelo
KMKadri Madissoo
Kadri Madissoo
ADAntonio Diaz-Lopez
Antonio Diaz-Lopez
CKCamilla Krakstad
Camilla Krakstad
MPMiguel Abal Posada
Miguel Abal Posada
About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC), we investigated the presence and phenotypic features of Circulating Tumor Cells (CTC) in high-risk EC patients. CTC isolation was carried out in peripheral blood samples from 34 patients, ranging from Grade 3 Stage IB to Stage IV carcinomas and recurrences, and 27 healthy controls using two methodologies. Samples were subjected to EpCAM-based immunoisolation using the CELLection™ Epithelial Enrich kit (Invitrogen, Dynal) followed by RTqPCR analysis. The phenotypic determinants of endometrial CTC in terms of pathogenesis, hormone receptor pathways, stem cell markers and epithelial to mesenchymal transition (EMT) drivers were asked. Kruskal-Wallis analysis followed by Dunn’s post-test was used for comparisons between groups. Statistical significance was set at p < 0.05. EpCAM-based immunoisolation positively detected CTC in high-risk endometrial cancer patients. CTC characterization indicated a remarkable plasticity phenotype defined by the expression of the EMT markers ETV5, NOTCH1, SNAI1, TGFB1, ZEB1 and ZEB2. In addition, the expression of ALDH and CD44 pointed to an association with stemness, while the expression of CTNNB1, STS, GDF15, RELA, RUNX1, BRAF and PIK3CA suggested potential therapeutic targets. We further recapitulated the EMT phenotype found in endometrial CTC through the up-regulation of ETV5 in an EC cell line, and validated in an animal model of systemic dissemination the propensity of these CTC in the accomplishment of metastasis. Our results associate the presence of CTC with high-risk EC. Gene-expression profiling characterized a CTC-plasticity phenotype with stemness and EMT features. We finally recapitulated this CTC-phenotype by over-expressing ETV5 in the EC cell line Hec1A and demonstrated an advantage in the promotion of metastasis in an in vivo mouse model of CTC dissemination and homing.